Reuters Health Report

Click to View in Browser 03/31/2014 Obamacare website stalls briefly ahead of enrollment deadline WASHINGTON (Reuters) - The website for people to enroll in U.S. private health insurance faced some delays early Monday morning, just hours before the deadline for the first year of enrollment under the healthcare law. Supreme Court declines to hear new contraception cases WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to take up preliminary appeals brought by Roman Catholic groups that want an exemption from part of President Barack Obama's healthcare law requiring employers to provide insurance that covers contraception. Novartis closes heart drug study early after strong results ZURICH (Reuters) - Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine. Weight loss surgery helps reverse type 2 diabetes for some: study WASHINGTON (Reuters) - Bariatric weight loss surgery on obese patients with type 2 diabetes helped many to get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday. GSK CEO says success of heart drug 'an open question' (Reuters) - The success or failure of GlaxoSmithKline's experimental heart drug darapladib remains "an open question" and will hinge on a second pivotal clinical study, the company's chief executive said on Monday. FDA allows Curis to resume testing cancer drug (Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Bayer gets EU nod to widen use of lung drug Adempas FRANKFURT (Reuters) - German drugmaker Bayer said on Monday it won approval in the European Union to widen the use of lung drug Adempas to two life-threatening forms of pulmonary hypertension. GSK pulls bid to extend use of kidney drug to ovarian cancer LONDON (Reuters) - GlaxoSmithKline on Monday withdrew an application to use Votrient, a drug licensed for kidney cancer, to treat advanced ovarian cancer after analysis of data from a late-stage trial did not support the benefit-to-risk ratio. Takeda Pharma says Japan approves two flu vaccine drugs TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd said on Monday it had received approval to manufacture and supply two vaccines for prevention of pandemic influenza from the Japanese health ministry. Drugmaker GSK to invest $200 million in African factories, R&D (Reuters) - Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as chronic diseases become more common among the continent's swelling urban middle classes. Related Video 'Noah' pours down on 'Divergent', 'Muppets' at U.S. box office Student sees the light with walking power The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend